Ascend Capital LLC Has Upped Puma Biotechnology INC (PBYI) Position by $78.14 Million as Stock Value Declined

January 20, 2018 - By Ellis Scott

Investors sentiment increased to 1.55 in 2017 Q3. Its up 0.34, from 1.21 in 2017Q2. It increased, as 19 investors sold PBYI shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. Rock Springs Capital Management Lp holds 330,000 shares or 1.82% of its portfolio. Proshare Advisors Ltd Liability has 0% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI). Kazazian Asset Management Ltd Liability invested 0.6% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Tekla Capital Ltd Liability Corp invested in 0.45% or 105,495 shares. J Goldman LP has invested 0.1% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Metropolitan Life Ny reported 19,626 shares. Invesco Limited accumulated 69,879 shares or 0% of the stock. Credit Suisse Ag owns 40,750 shares. 500 were reported by Plante Moran Financial Advsr. Franklin Street Advsrs Nc invested 0.43% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Sanctuary Wealth Ltd Liability Com holds 3.32% or 35,788 shares in its portfolio. Northern Tru, a Illinois-based fund reported 345,860 shares. Quantitative Invest Mgmt Limited Liability Company invested in 0.04% or 30,000 shares. Northwestern Mutual Wealth Mngmt Company has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Ameriprise Fincl holds 165,547 shares.

Since September 6, 2017, it had 0 insider buys, and 2 sales for $3.30 million activity.

Malcolm Fairbairn increased its stake in Puma Biotechnology Inc (PBYI) by 1093.43% based on its latest 2017Q3 regulatory filing with the SEC. Ascend Capital Llc bought 656,662 shares as the company’s stock declined 6.09% while stock markets rallied. The hedge fund run by Malcolm Fairbairn held 716,717 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $85.83 million, up from 60,055 at the end of the previous reported quarter. Ascend Capital Llc who had been investing in Puma Biotechnology Inc for a number of months, seems to be bullish on the $3.44 billion market cap company. The stock increased 3.80% or $3.35 during the last trading session, reaching $91.6. About 640,899 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has risen 23.65% since January 20, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.

Ascend Capital Llc, which manages about $4.98B and $2.65B US Long portfolio, decreased its stake in Monster Beverage Corp New by 188,789 shares to 114,030 shares, valued at $6.30 million in 2017Q3, according to the filing. It also reduced its holding in Kraft Heinz Co by 360,292 shares in the quarter, leaving it with 106,477 shares, and cut its stake in Mallinckrodt Pub Ltd Co (NYSE:MNK).

More news for Puma Biotechnology, Inc. (NASDAQ:PBYI) were recently published by:, which released: “Form SC 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: JANUS HENDERSON GROUP PLC” on January 10, 2018.‘s article titled: “Puma Biotech (PBYI) to Modify Neratinib MAA Based on Feedback from CHMP’s SAG” and published on January 11, 2018 is yet another important article.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Ratings Coverage

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Puma Biotechnology Inc has $164 highest and $36 lowest target. $119’s average target is 29.91% above currents $91.6 stock price. Puma Biotechnology Inc had 49 analyst reports since August 27, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 9 by Cowen & Co. The firm earned “Outperform” rating on Monday, July 10 by Leerink Swann. The firm earned “Buy” rating on Monday, June 5 by J.P. Morgan. On Monday, July 17 the stock rating was maintained by RBC Capital Markets with “Hold”. The rating was maintained by J.P. Morgan on Tuesday, July 18 with “Buy”. RBC Capital Markets maintained it with “Sector Perform” rating and $108 target in Friday, November 10 report. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Buy” rating by Credit Suisse on Tuesday, July 18. The firm earned “Outperform” rating on Thursday, September 22 by Credit Suisse. As per Wednesday, September 27, the company rating was maintained by Credit Suisse. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Hold” rating by RBC Capital Markets on Wednesday, October 25.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.